HONG KONG – In late May, the China National Drug Administration (CNDA), along with four other bodies, published the list of rare diseases that includes 121 indications, with the aim of encouraging research and development of orphan drugs and speeding up their marketing in China, all the while making those drugs more affordable for patients.